SAGE Sage Therapeutics Inc.

164.98
+4.49  (+3%)
Previous Close 160.49
Open 161.15
Price To Book 7.08
Market Cap 8,522,370,705
Shares 51,656,993
Volume 62,118
Short Ratio
Av. Daily Volume 378,787

NewsSee all news

  1. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  2. Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder

    Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently

  3. Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data due 4Q 2019 or 1Q 2020.
SAGE-217 - MOUNTAIN
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
SAGE-217
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
SAGE-547
SRSE
Phase 3 data due 2020.
SAGE-217 - RAINFOREST
Insomnia
Phase 2 Part A data July 24, 2019 noted MADRS score of 15.5 points at Day 15 (n=23; p<0.0001) - secondary endpoint.
SAGE-217 - ARCHWAY
Bipolar depression
Phase 1 data released July 24, 2019 noted treatment in healthy volunteers was well tolerated.
SAGE-718
Huntington's disease
Phase 2 trial to be initiated 2H 2019.
SAGE-324
Essential tremor
Phase 3 data due 2020.
SAGE-217 - SHORELINE
Major Depressive Disorder (MDD)

Latest News

  1. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  2. Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder

    Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently

  3. Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the